Fraiser Kansteiner, Eric Sagonowsky, Zoey Becker, Kevin Dunleavy, Angus Liu, Fierce Pharma; The top 10 drugs losing US exclusivity in 2023
"Across the industry this year, big-selling drugs from Johnson & Johnson, Takeda, AstraZeneca, Roche and other companies are set to face their first generic or biosimilar challengers in the U.S. As always, the patent expirations should create quite a shake-up for many of the industry’s top players."
